An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia.
Ibai Los ArcosJoaquin BurgosVicenç FalcóBenito AlmirantePublished in: Expert opinion on pharmacotherapy (2020)
The results of a randomized clinical trial have demonstrated an efficacy and safety profile of ceftolozane-tazobactam similar to that of its comparator for the treatment of patients with HAP/VAP. Several retrospective studies have shown good efficacy of the drug for the treatment of respiratory infections caused by MDR P. aeruginosa. The use of this drug may be incorporated as a new therapeutic option for the treatment of patients with HAP/VAP in a carbapenem-saving setting or as a therapeutic alternative with a better safety profile than other therapeutic options in patients with infections caused by MDR P. aeruginosa.